Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving expanded FDA approval for its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys.

Sarepta Therapeutics Stock Soars on FDA Approval

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use of its gene therapy Elevidys for patients with Duchenne muscular dystrophy (DMD). DMD is a rare genetic condition which causes weakness and the wasting away of the body's muscles, with symptoms including trouble walking and running, falling frequently, fatigue and learning disabilities or difficulties.

Sarepta Therapeutics shares surge as muscular dystrophy therapy approved for expanded use

Sarepta Therapeutics (NASDAQ: SRPT ) stock jumped about 30% overnight after the Food and Drug Administration (FDA) approved one of its gene therapies for children with Duchenne muscular dystrophy (DMD). Peter Marks, director of the Center for Biologics Evaluation and Research, overruled three research teams and his top lieutenants in making the decision.

Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost

Sarepta Therapeutics (SRPT) shares soared in premarket trading Friday, a day after the Food and Drug Administration (FDA) allowed expanded use of the biotech's treatment for a rare muscle disease in children, which especially affects boys.

Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug

Sarepeta Therapeutics Inc.'s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle disorder Duchenne muscular dystrophy.

Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug

The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.

Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks.

Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc's SRPT Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age.

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy

Sarepta Therapeutics shares surged about 36% in premarket trading on Friday as an expanded use approval opened up a bigger market in the U.S. for its gene therapy for patients with Duchenne muscular dystrophy (DMD).

Sarepta surges as investors cheer expanded use of gene therapy

Sarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price shoot up by 36% in after-hours trading last night. But why? Ground-breaking medical breakthrough Toward the end of the trading day yesterday, Sarepta announced that it had obtained approval from the U.S.

Why has the Sarepta stock price (SRPT) gone up more than 35%?

Sarepta rocketed late Thursday after the FDA approved its Duchenne muscular dystrophy gene therapy for all patients age 4 and older.

Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy

Sarepta Therapeutics Inc (NASDAQ: SRPT) rallied a whopping 40% in extended hours today following a key announcement from the U.S. Food and Drug Administration regarding Elevidys.  Elevidys is the company's treatment for Duchenne muscular dystrophy.

Sarepta Therapeutics receives expanded approval for Elevidys

The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' gene therapy for all patients with Duchenne muscular dystrophy aged four and above on Thursday.

US FDA approves expanded use of Sarepta's Duchenne gene therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics announces the expanded U.S. FDA approval of ELEVIDYS to Duchenne muscular dystrophy patients ages 4 and above.

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Roche initiated the process for Elevidys marketing authorization application in Europe, expected to be completed by H1 2024. If successful, Elevidys label and geographic expansion is likely to unlock Sarepta's capacity to maintain a strong revenue growth pattern. Thus, supporting a “buy” rating for SRPT.

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

Pfizer

Shares of Sarepta Therapeutics Inc. SRPT, -1.15% gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial.

Pfizer's gene-therapy trial failure boosts Sarepta's stock

Casella Waste Systems

Datadog

If a portfolio is passively managed, investors tend to buy and forget. This however holds true for high-quality blue-chip and growth stocks.

Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate

Sarepta Therapeutics (NASDAQ:SRPT) is set to make a significant move by entering the S&P MidCap 400 index, replacing Shockwave Medical. This change, effective before trading begins on June 3, 2024, follows Johnson & Johnson's acquisition of Shockwave Medical.

Sarepta Therapeutics stock to enter S&P MidCap 400: Should you buy?

CRISPR Therapeutics

Vertex Pharmaceuticals

With the interest cuts coming up, it's an ideal time to consider loading up on the top biotech stocks. These stocks continue to dazzle with game-changing medical breakthroughs and explosive growth potential.

The 2030 Millionaire's Club: 3 Biotech Stocks to Buy Now

Regeneron Pharmaceuticals

Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untreatable conditions.

3 Biotech Stocks With the Potential to Make You an Overnight Millionaire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year. Dr. Mendell was recognized for his lifetime commitment to neuromuscular disease and achievements in genetic medicine that propell.

Gene Therapy Pioneer Jerry R. Mendell, M.D.

Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.97 per share a year ago.

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations & Corporate Communications Douglas Ingram - President & Chief Executive Officer Dallan Murray - Executive Vice President & Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer & Head of Research & Development Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Participants Operator Good afternoon and welcome to the Sarepta Therapeutics First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

News for Sarepta Therapeutics Stock (SRPT)